3,4-Dihydroxybenzylamine hydrobromide (NSC-263475 hydrobromide) inhibits DNA polymerase activity in melanoma cells and displays growth inhibitory activity in melanoma cell lines with varying degrees of tyrosinase activity.

3,4-Dihydroxybenzylamine hydrobromide (1 μM-10 mM; 48 hours) inhibits the growth of melanoma cell lines with IC50 values of 30, 84, 90, and 68 μM for SK-MEL-30, SK-MEL-2, SK-MEL-3, and RPMI-7951 cells, respectively, and exhibits IC50 values of 10, 25, 67, and 184 μM for S91A, S91B, L1210, and SCC-25 cells. Cytotoxicity in SK-MEL-2 and SK-MEL-28 is enhanced by buthionine sulfoximine (BSO), decreasing the IC50 values of 3,4-DHBA by 127% in SK-MEL-28 and by 148% in SK-MEL-2 cells[1].

3,4-Dihydroxybenzylamine hydrobromide (200, 400, 600 and 800 mg/kg; i.p.; 21 days) has different effects at different doses, the median life-span are 17, 24.5, 26, 29 and 25 days respectively. 3,4-Dihydroxybenzylamine hydrobromide (1000 mg/kg; i.p.; 7 days) has the least toxic effect in non-tumor-bearing B6D2F1 mice,and mice is tolerated at this dose[2].

Cell Line: Human and Murine Melanoma Cell Lines; Non-Melanoma Cell Lines
Concentration: 1 μM-10 mM
Incubation Time: 48 hours [1]

Animal Model: C57BL/6 mice with B6D2F1 cells
Dosage: 200 mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg
Administration: Intraperitoneal injection [2]